Last reviewed · How we verify
Paclitaxel +/- Tislelizumab
Paclitaxel is a microtubule-stabilizing chemotherapy agent combined with tislelizumab, a PD-1 inhibitor that enhances anti-tumor immune response.
Paclitaxel is a microtubule-stabilizing chemotherapy agent combined with tislelizumab, a PD-1 inhibitor that enhances anti-tumor immune response. Used for Breast cancer (phase 3 trial, specific subtype under investigation).
At a glance
| Generic name | Paclitaxel +/- Tislelizumab |
|---|---|
| Sponsor | SOLTI Breast Cancer Research Group |
| Drug class | Combination therapy: microtubule stabilizer + PD-1 inhibitor |
| Target | Microtubules (paclitaxel); PD-1 (tislelizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel works by binding to and stabilizing microtubules, preventing cell division and inducing apoptosis in cancer cells. Tislelizumab is a humanized monoclonal antibody that blocks PD-1 on T cells, releasing immune checkpoint inhibition and allowing enhanced anti-tumor immune activity. The combination aims to leverage both direct cytotoxic chemotherapy and immunotherapy synergy.
Approved indications
- Breast cancer (phase 3 trial, specific subtype under investigation)
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Fatigue
- Immune-related adverse events (irAEs)
- Infusion reactions
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- IN10018 Combination Therapy in Previously-treated Solid Tumors (PHASE1, PHASE2)
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (PHASE2)
- A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] (PHASE2)
- Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma (PHASE2)
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) (PHASE3)
- Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel +/- Tislelizumab CI brief — competitive landscape report
- Paclitaxel +/- Tislelizumab updates RSS · CI watch RSS
- SOLTI Breast Cancer Research Group portfolio CI